Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy, discusses the use of cognitive behavioral therapy (CBT) as a first-line treatment for chronic insomnia and barriers limiting its use.
The minimal adverse effects of cognitive behavioral therapy (CBT) and its efficacy compared with medication have led to its recommendation as a first-line treatment for chronic insomnia, but access issues remain, said Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy.
Transcript
Can you speak on the emergence of CBT for chronic insomnia?
Emergence of CBT for chronic insomnia (CBT-I) goes back a little bit. So, when I look at guidelines from 2016, 2017, or even earlier guidelines than that, CBT-I is the first-line treatment for a few reasons.
One, it's been shown to be just as effective as medications are. And 2, there's a lot less side effects, and some would even say no side effects at all. Others say that for some people, their insomnia gets a little worse before it gets better, but other than that, there's no other systemic effects or side effects like there are with medications.
So, due to these reasons, CBT-I is promoted by the guidelines, the governing bodies, physicians, providers, so that's why there's been such an emergence of this type of therapy. The biggest issue really is access. We know CBT-I works, but there's not many providers specifically trained in how to administer CBT-I, so that's one of the biggest barriers: access.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More